Zobrazeno 1 - 10
of 347
pro vyhledávání: '"Pär Stattin"'
Publikováno v:
European Urology. 82:e115
Autor:
Pär Stattin, Ola Bratt
Publikováno v:
European urology. 71(4)
Autor:
Glen Denmer Santok, Koon Ho Rha
Publikováno v:
European urology. 71(4)
Publikováno v:
International Journal of Cancer. 151:1925-1934
Androgen deprivation therapy (ADT) has been hypothesized to protect against COVID-19, but previous observational studies of men with prostate cancer on ADT have been inconsistent regarding mortality risk from coronavirus disease 2019 (COVID-19). Usin
Autor:
Tiago M. Bonde, Marcus Westerberg, Markus Aly, Martin Eklund, Jan Adolfsson, Anna Bill-Axelson, Hans Garmo, Pär Stattin, David Robinson
Publikováno v:
Scandinavian Journal of Urology. 56:169-175
Objectives: To predict castration-resistant prostate cancer (CRPC) and prostate cancer (Pca) death by use of clinical variables at Pca diagnosis and PSA levels after start of gonadotropin-releasing hormone agonists (GnRH) in men with non-metastatic c
Autor:
Charlotte Alverbratt, Hanna Vikman, Marie Hjälm Eriksson, Pär Stattin, Ingela Franck Lissbrant
Publikováno v:
Scandinavian Journal of Urology. 56:95-101
Background Patients with advanced prostate cancer (PCa) typically undergo numerous lines of treatment leading to large amounts of information in Electronic Health Records (EHRs). The Patient-overview Prostate Cancer (PPC) presents clinical informatio
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-9 (2022)
BMC Urology
BMC Urology
Background: Epidemiological data on anticoagulation for venous thromboembolism (VTE) in prostate cancer are sparse. We aimed to investigate associations between anticoagulation duration and risks of VTE recurrence after treatment cessation and major
Autor:
Eugenio, Ventimiglia, Anna, Bill-Axelson, Ola, Bratt, Francesco, Montorsi, Pär, Stattin, Hans, Garmo
Publikováno v:
JAMA network open. 5(9)
The long-term outcomes among men with prostate cancer (PC) whose disease is managed with active surveillance (AS) remains unknown.To develop a simulation model with a 30-year follow-up for men with PC managed with AS.In this cohort study, a state tra
Autor:
Pär, Stattin
Publikováno v:
Scandinavian journal of urology. 56(4)
Autor:
E. Lin, Hans Garmo, Mieke Van Hemelrijck, Björn Zethelius, Pär Stattin, Emil Hagström, Jan Adolfsson, Danielle Crawley
Publikováno v:
JAMA network open. 5(8)
IMPORTANCE Men with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Meanwhile, gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer (PCa) are associated with increased risk of CVD. OBJECTIVE To evaluate the a